
Jasper Therapeutics Inc. (NASDAQ:JSPR) on Tuesday released preliminary data from the ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma.
A single subcutaneous 180mg dose of briquilimab demonstrated substantial reductions in sputum eosinophils at both six and twelve weeks, as well as improvements over baseline in FEV1 (key indicator of lung function) in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR).